Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
Seasonal influenza vaccination and antiviral use in EU/EEA Member States
Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons.
Table of contributions for the expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza
The 'Table of contributions' contains all comments received through a public consultation on this topic and lists ECDC’s responses to those comments.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Recommendations on antivirals in European countries are appropriate, but remain underutilised in practice
Current recommendations in EU countries to use neuraminidase inhibitors (antivirals) for patients with severe influenza are supported by the available evidence, concludes a new expert opinion report from ECDC which is now open for public consultation.
New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published
This evaluated patients admitted to hospital with laboratory-confirmed or clinically diagnosed influenza A H1N1pdm09 virus infection.
How effective were neuraminidase inhibitors during the 2009 pandemic?Archived
This systematic review and meta-analysis of observational data from an established group of specialists assessed treatment outcomes for all three neuraminidase inhibitors (NAIs); oseltamivir, zanamivir and peramivir given to hospitalised patients with influenza A(H1N1)pdm09 during the 2009 pandemic.
Two evaluations of the response to the 2009 Pandemic in Spain: Surveillance and Vaccines and antiviralsArchived
Two official evaluations have been made by the national Ministry of Health of Spain of their country’s response to the 2009 influenza pandemic. The reviews focused on two particular topics - Surveillance and Vaccines and Antivirals.
Global Review of recent Antiviral Resistance dataArchived
Each year in February WHO convenes a meeting with advisers from the WHO Influenza Collaborating Centres and Essential Reference laboratories in order to achieve consensus and advise WHO on the optimal formulation of seasonal influenza vaccines for the next influenza season.